Related Experiment Video
Updated: Apr 27, 2026

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
Outcome after heart transplantation from older donor age: expanding the donor pool
David Prieto1, Pedro Correia1, Manuel Baptista1
1Center of Cardiothoracic Surgery, University Hospital and Medical School, Coimbra, Portugal.
Insights
Using hearts from older donors (>50 years) shows similar short-term survival and mortality rates compared to younger donors (<40 years) in heart transplantation. Selected marginal donors with shorter ischemic times do not negatively impact outcomes.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- Heart donor selection criteria have expanded, including higher age limits.
- The use of older donor hearts is increasingly considered to address organ shortages.
Purpose of the Study:
- To analyze the impact of using hearts from older donors (≥50 years) on heart transplant outcomes.
- To compare recipients of older donor hearts with those of younger donor hearts.
Main Methods:
- A retrospective analysis of 228 heart transplantations between November 2003 and December 2012.
- Exclusion of pediatric recipients and those requiring ventricular assistance.
- Comparison of recipients from 26 donors aged ≥50 years (Group A) with 136 donors aged <40 years (Group B).
Main Results:
- Group A recipients were older and had longer waiting times, but 30-day mortality was similar (3.8% vs 3.7%).
- Actuarial survival at 1, 3, and 5 years was comparable between groups (84% vs 90% at 1 year).
- A trend towards decreased survival free from cardiac allograft vasculopathy (CAV) was observed in Group A (65% vs 78% at 8 years).
Conclusions:
- Selected marginal donor hearts, particularly those with shorter ischemic times, can be used without negatively impacting morbidity and mortality.
- Donor selection criteria can be adjusted to include older donors, offering a viable option compared to waiting list mortality.
- While short-term outcomes are favorable, long-term monitoring for cardiac allograft vasculopathy is important.
Objectives:
There has been a progressive expansion of heart donor selection criteria, including higher age limit. We analysed the impact of using hearts from older age donors (>50 years).
Methods:
Between November 2003 and December 2012, 228 heart transplantations were performed. Children and patients requiring ventricular assistance prior to transplantation were excluded. Recipients from 26 donors aged ≥ 50 years (Group A) were compared with those of 136 donors <40 years (Group B). Patient and donor criteria were identical in both groups.
Results:
Group A recipients were older than those in Group B (59 ± 11 vs 53 ± 11; P < 0.01), and tended to have more ischaemic cardiomyopathy (50 vs 35%; P = 0.16), be in intensive care (31 vs 27%; P = 0.65) and have longer waiting time (56 ± 49 vs 41 ± 47 days; P = 0.15). There were also significant differences in ischaemic time (65 ± 27 vs 93 ± 35 min; P < 0.01). Thirty-day mortality was similar (3.8 vs 3.7%; P = 0.97). Follow-up was 55 ± 32 months. Actuarial survival at 1, 3 and 5 years was 84 ± 7% for Group A and 90 ± 3, 86 ± 3 and 81 ± 4%, respectively, for Group B (P = 0.85). There were no survival differences between patients younger and older than 60 years, but there was a tendency for decreased survival free from cardiac allograft vasculopathy (CAV) in Group A compared to Group B (at 8 years 65 ± 18 vs 78 ± 7%; P = 0.06).
Conclusions:
Parameters of exclusion of donor hearts can and must be adjusted, since the use of selected marginal donors associated with short ischaemic times appears to have no negative impact on morbidity and mortality, more importantly when compared with mortality on the waiting list.
Related Concept Videos
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant II: Surgical Procedure

